Effect of Ramadan fasting on serum concentration of apelin-13 and new obesity indices in healthy adult men

Ahmet Celik, Edibe Saricicek, Vahap Saricicek, Elif Sahin, Gokhan Ozdemir, Selim Bozkurt, Mehmet Okumus, Mustafa Haki Sucakli, Gurkan Cikim, Yasemin Coskun, Mustafa Saygin Deniz, Ekrem Dogan, Metin Kilinc

The aim of this study was to determine how Ramadan fasting (RF) affected the recently described new obesity indices [visceral adiposity index (VAI), waist circumference to height ratio (WHtR), body adiposity index (BAI)], and serum concentration of apelin-13 (RF) in healthy adult men.

For this purpose, 42 healthy adult men were selected. Anthropometric parameters were measured and a sample of venous blood was obtained for biochemical assays on the first and last days of Ramadan. When all subjects were evaluated, all anthropometric parameters changed except VAI. Serum apelin-13, triglyceride (TG), HDL-cholesterol (HDL-C), and insulin levels did not change. When patients were divided into 3 groups according to body mass index (BMI), BAI decreased in normal-weight subjects and WHtR decreased in other groups, but VAI and apelin-13 did not change in any groups.

We demonstrate for the first time that while some anthropometric parameters changed, VAI and serum apelin-13 levels did not change with RF. BMI, waist circumference (WC), TG, and HDL-C were evaluated together in calculation of VAI. TG, VAI, and HDL-C remained unchanged by RF. Even if body weight (BW) and BMI decreased, apelin-13 was not affected by RF. The data on serum apelin-13 may have been influenced by the small-percentage decrease in BW, as well as insignificant improvements in metabolic parameters such as lipid profiles, glucose, and insulin.

We found that Ramadan fasting in healthy adult men was associated with significant decreases in BW, BMI, WHtR, and BAI, but we found no significant changes in VAI and serum apelin-13 concentrations.

MeSH Keywords: Body Adiposity Index • Waist Circumference • Intra-Abdominal Fat • Apelin-13 • Fasting

http://www.medscimonit.com/download/index/idArt/890139
Background

Ramadan is the holiest month in the Islamic calendar and Muslims fast during this month. They abstain from eating and drinking from Sahur (the meal taken just before dawn during the Ramadan fast) until Iftar (sunset) during Ramadan, which is a lunar month of 29 or 30 days. This is referred to as Ramadan fasting (RF), which lasts from 8 to 18 hours, according to the season and latitude. Ramadan fasting entails major changes in sleep pattern, physical activity, and eating habits, which may cause changes in metabolism. Many aspects of these changes have been studied.

Visceral adiposity index (VAI), waist circumference-to-height ratio (WHtR), and body adiposity index (BAI) are newly described obesity indices [1–5]. The VAI is postulated to be a good indicator of visceral obesity and insulin sensitivity and is significantly correlated with visceral adiposity. Increased VAI has been found to be strongly associated with cardio-metabolic risk [2–6].

Apelin is a bioactive peptide that is synthesized and secreted by adipocytes [7]. Its gene encodes a pre-proprotein that is processed to generate bioactive peptides consisting of 36, 17, or 13 amino acids (apelin-36, apelin-17, and apelin-13, respectively). Apelin-13 acts primarily in the peripheral and central nervous systems, playing important roles in regulating cardiovascular function, fluid homeostasis, and hypertension, as well as regulating eating behavior, gastrointestinal function, and insulin sensitivity [8–10].

We aimed to investigate how new anthropometric obesity parameters (VAI, WHtR and BAI) and serum concentration of apelin-13 are affected by RF in healthy adult men.

Material and Methods

This study was conducted in the month of Ramadan, from 20 July to 20 August, 2012 in Kahramanmaras. The length of the fasting was 15-16 hours per day and the mean temperature was 35°C. The study adhered to the guidelines of the Declaration of Helsinki and all procedures were approved by the Sutcu Imam University Institutional Research Ethics Committee (2012/14-4). Written informed consent was obtained from all subjects.

Subjects

The study included 42 healthy males without any disease or drug use, with a mean age of 35.0±8.9 years, who declared that they would fast for the entire month of Ramadan. The subjects were divided into 3 groups according to the World Health Organization (WHO) criteria of BMI as normal (n=15), overweight (n=17) and obese (n=10).

Anthropometric parameters

A 10-mL fasting blood sample of was collected twice from the median cubital vein by using a vacuum sampling method from each subject. Height, body weight (BW), waist circumference (WC), and hip circumference (HC) were measured for twice on the first day (R1) and last day (R2) of Ramadan at 11:00 a.m. (8–9 hours after the last meal [Sahur]). Serum aliquots were preserved at ~80°C until biochemical analyses.

BMI, waist circumference-to-hip circumference ratio (WHHR), WHtR, VAI, and BAI were calculated. The BW, height, WC (measured at a level midway between the lowest rib margin and the iliac crest), and HC (widest diameter over the greater trochanters) were measured using standardized procedures to calculate obesity indices as follows [5]:

\[ WHtR = \frac{\text{Waist circumference (cm)}}{\text{Height (cm)}} \]

\[ VAI = \left[ \frac{\text{WC}}{\left(39.68+1.88\times\text{BMI}\right)} \right] \times \left[ \frac{\text{TG (mmol/L)}}{1.03} \right] \times \left[ \frac{1.31}{\text{HDL-C (mmol/L)}} \right] \text{ (for males)} \]

\[ \text{BAI} = \left( \frac{\text{HC}}{\text{height}^{1.5}} \right) - 18 \]

Biochemical Assays

Serum Triglyceride (TG), Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were analyzed using standard methods.

Serum apelin-13 levels were determined with ELISA (enzyme-linked immunosorbent assay) method by using a commercial kit (USCN Life Science Inc.), an automatic ELISA microplate reader (Thermo Scientific, Finland), and a computer program (SkanIt for Multiscan FC 2.5.1). Sensitivity was 37.2 pg/mL and the detection range was 98.8–8000 pg/mL. Intra-assay CV was <10% and inter-assay CV was <12%. Results were observed as ng/mL.

Statistical analysis

Results are expressed as mean ±SD, number, and percent. Data were analyzed in SPSS Program 15.0 (SPSS Inc., Chicago, IL, USA). Paired t test (in all subjects) and Wilcoxon t test (in groups according to BMI) were used to match variables between R1 and R2. Statistical significance was assumed when the p-value was less than 0.05.

Results

Demographic, anthropometric and biochemical data obtained from the subjects at R1 and R2 with p values are listed in Table 1. All anthropometric measurements except VAI were
decreased at R2 (p<0.05). Glucose, TC, and LDL-C increased and TG, HDL-C, insulin, and apelin-13 remained unchanged.

The demographic, anthropometric, and biochemical data of groups according to BMI score with p values are listed in Table 2. BAI decreased in normal-weight subjects and WHtR decreased in overweight and obese subjects at R2.

BW was decreased in 35 subjects and increased in 7 subjects (2 normal-weight and 5 overweight). Mean decreases of BW were 2.61% in all subjects and 2.7%. 2.17%, and 2.61% in normal-weight, overweight, and obese subjects, respectively. VAI, WHR, and BAI were decreased in subjects who lost weight, but there was no significant difference in subjects who gained weight. When subjects who gained weight were excluded, apelin-13 was not significantly different.

Discussion

In this study, we demonstrate for the first time that apelin-13 was not affected by RF in all subjects and in groups according to BMI. Some studies reported that decreasing of serum apelin levels was associated with reduction in BMI by diet, exercise program, and bariatric surgery [11,12]. Krist et al. and Castan et al. established that decreases in serum apelin levels and improved insulin sensitivity, fasting blood glucose, and other metabolic indices were simultaneous. In our study, while some anthropometric parameters were improved, TC, LDL, glucose and insulin levels increased at the end of RF. These results may be due to insignificant differences of serum apelin-13 levels between R1 and R2.

In contrast, Heinonen et al. reported that no significant change in plasma apelin was observed in men and women with metabolic syndrome despite substantial and sustained improvements in body weight, BMI, body adiposity, and glucose metabolism, and a small improvement in blood pressure in response to a very low-calorie diet and 6-month weight maintenance period [13]. In our study, the weight loss rates were lower and the period was shorter than in the study by Heinonen et al. In addition, none of the subjects in our study had metabolic syndrome. Our findings are similar to those of Heinonen et al. When we evaluated the subjects who lost weight (mean weight loss was 2.61%), no significant difference was obtained between R1 and R2 in serum apelin-13 levels.

| Table 1. Biochemical and anthropometric parameters of all subjects in R1 and in R2 (n=42). |
|------------------------------------------|-----------------|-----------------|-----------------|
| parameters             | R1              | R2              | p value         |
| Age, years             | 35.0±8.9        |                 |                 |
| Smoking, n             |                 | 3               |                 |
| BW, kg                 | 80.4±14.3       | 78.8±13.7       | <0.001          |
| WC, cm                 | 95.4±11.9       | 94.3±11.4       | <0.001          |
| HC, cm                 | 104.6±7.8       | 104.0±7.5       | 0.001           |
| WHR                    | 0.91±0.05       | 0.90±0.05       | 0.005           |
| WHR                    | 0.55±0.07       | 0.54±0.07       | <0.001          |
| BMI, kg/m²             | 26.64±4.40      | 26.11±4.18      | 0.001           |
| BAI                    | 27.78±3.51      | 27.51±3.58      | 0.001           |
| VAI                    | 1.82±1.21       | 1.7±1.01        | 0.364           |
| Glucose, mg/dL         | 74.2±12.67      | 84.2±10.71      | <0.001          |
| Insulin, µU/mL         | 6.51±3.21       | 7.05±3.52       | 0.406           |
| TC, mg/dL              | 170.4±40.9      | 182.4±36.7      | <0.001          |
| TG, mmol/L             | 1.38±0.79       | 1.31±0.72       | 0.447           |
| HDL-C, mmol/L          | 1.09±0.19       | 1.1±0.19        | 0.744           |
| LDL-C, mg/dL           | 100.1±30.8      | 110.6±27.9      | <0.001          |
| Apelin 13, ng/mL       | 4.64±0.92       | 4.19±1.26       | 0.069           |

Table 1 was obtained from anthropometric and biochemical data of all subjects by using paired t test. BAI – body adiposity index; BMI – body mass index; HDL-C – high-density lipoprotein cholesterol; HC – hip circumferences; LDL-C – low-density lipoprotein cholesterol; TC – total cholesterol; TG – triglyceride; VAI – visceral adiposity index; WC – waist circumference; WHR – waist circumferences-to-hip circumferences ratio; WHtR – waist circumference-to-height ratio.
Table 2. Biochemical and anthropometric parameters of normal, overweight and obese subjects in R1 and in R2.

| Parameters                  | In normal (n=15) | In overweight (n=17) | In obese (n=10) | p values |
|-----------------------------|------------------|----------------------|-----------------|----------|
| Age, years                  | 29.5±7.7         | 39.4±7.0             | 36.0±10.5       |          |
| Smoking, %                  | 0                | 11.8                 | 14.3            |          |
| BW, kg                      | 69.1±7.3         | 81.8±6.8             | 101.1±15.1      | 0.000    |
| WC, cm                      | 85.5±6.6         | 97.2±4.5             | 112.3±12.4      | 0.061    |
| HC, cm                      | 98.4±4.8         | 106±4.1              | 114.6±8.7       | 0.202    |
| WHR                         | 0.87±0.04        | 0.92±0.03            | 0.98±0.05       | 0.13     |
| WHR                         | 0.49±0.04        | 0.56±0.03            | 0.65±0.07       | 0.075    |
| BMI, kg/m²                  | 22.8±1.63        | 22.45±1.57           | 33.45±4.44      | 0.006    |
| BAI                         | 26.96±2.13       | 26.69±2.06           | 31.79±3.61      | 0.028    |
| VAI                         | 1.16±0.72        | 1.18±0.6             | 2.73±0.71       | 0.82     |
| Glucose, mg/dL              | 68.8±8.4         | 76.7±13.5            | 79.4±15.7       | 0.001    |
| Insulin µU/mL               | 5.37±2.79        | 6.37±3.32            | 9.30±2.25       | 0.887    |
| TC, mg/dL                   | 148.9±24.4       | 174.3±30.4           | 205.3±39.5      | <0.001   |
| TG, mmol/L                  | 81.9±27.4        | 135.0±85.4           | 175.6±46.3      | 0.798    |
| HDL-C, mmol/L               | 44.5±8.1         | 41.2±7.5             | 39.1±3.7        | 0.777    |
| LDL-C, mg/dL                | 83.1±19.1        | 102.2±25.7           | 129.7±29.7      | 0.001    |
| Apelin 13, ng/mL            | 4.41±0.96        | 3.91±1.14            | 5.21±1.04       | 0.14     |

p1: between R1 and R2 in normal; p2: between R1 and R2 in overweight; p3: between R1 and R2 in obese.

In regulating cardiovascular function, apelin inhibits water intake and vasopressin production [10,14]. Water deprivation, while increasing the activity of vasopressin neurons, reduces plasma apelin concentrations and induces an intra-neuronal accumulation of the peptide, thereby decreasing the inhibitory effect of apelin on vasopressin release and preventing additional water loss at the kidney level. Apelin counteracts the effects of vasopressin in the maintenance of body fluid homeostasis [15]. Apelin expression in fat cells is strongly inhibited by fasting and recovered after re-feeding [5]. Intracerebroventricularly injected apelin-13 inhibits gastric emptying and gastrointestinal transit [16]. Apelin has been shown to be involved in stimulating gastric cell proliferation, cholecystokinin (CCK) secretion, histamine release, gastric acid and bicarbonate secretion, and regulation of gastrointestinal motility [17,18]. Fasting for 30 days did not significantly affect circulating apelin-13 levels. Subjects in the present study did not have any disorders or diseases. We hypothesize that if we had taken subjects having conditions such as higher BMI, hypertension, and metabolic syndrome, we might have found significant differences in serum concentrations of apelin-13 during RF.

Other findings of our study involved anthropometric parameters. BAI decreased in normal-weight subjects and WHR decreased in overweight and obese subjects. These findings mean the abdominal fat reduction was more marked in overweight and obese subjects. WHO reported that BMI value should be between 18.5 and 24.9 kg/m² and median value should be between 21.0 and 23.0 to achieve and maintain optimal health conditions [19]. In our study, median BMI value was 26.2 on the first day of Ramadan and 25.5 on the last day, which is closer to the WHO target. These findings may be seen as a positive effect of RF on health. According to WHO, at least 2.8 million people die each year due to overweight or obesity. Being overweight or obese drastically increases risk of noncommunicable diseases such as cardiovascular disease, cancer, and DM.
There is increased co-morbidity for overweight individuals and severe co-morbidity for obese individuals. Both general and abdominal adiposity are related to the risk of death [20–22].

The majority of health-specific findings related to RF are equivocal. A previous study measured the effects of RF on BMI, WHR, and abdominal and visceral fat distribution measured by CT, finding that BMI and BW were not changed, but the visceral fat compartment was reduced in women and young subjects because they were more physically active [23]. Another study reported that restriction in feeding, reduction in activity, and increased sleeping time may be the causes of increased BW. In contrast, decreased total amount of food consumed per day and non-decreased physical activity together during RF may be the causes of reduction in BW [24].

In our study, the results revealed that in addition to VAI, the levels of TG and HDL did not change. VAI is measured by using BMI, WC, TG, and HDL [5]. Some studies reported that HDL-C significantly increased and there was a non-significant rise in the TG value together with weight loss at the end of Ramadan fasting [24–27]. Unalacak et al. reported that no significant difference was found in HDL-C, LDL-C, and TG in normal-/weight and obese subjects following RF [28]. On the contrary, Ziaee et al. showed reductions in concentrations of blood glucose and HDL, and increases in LDL, in healthy individuals during RF [29].

Changes in anthropometric and biochemical parameters are variable and depend on the quality and quantity of food intake, physical activity and exercise, changes in body weight, and biochemical response to starvation [24–30]. Differences in the results of glucose, TC, LDL-C, TG, and HDL-C detected in our study may be related to these factors. Hence, the changes that occurred following 30 days of fasting were not sufficient to affect VAI.

**Limitations**

We did not investigate the effects of calorie intake and energy expenditure, sleeping harmony, and diurnal rhythm-related hormones, and we did not follow up the effects of RF. Because all subjects were healthy, insulin resistance and sensitivity and their relation with apelin-13 were not examined.

**Conclusions**

There were significant decreases in BW, BMI, WHtR, and BAI, but no significant variation in VAI and serum apelin-13 concentrations during Ramadan fasting in healthy adult men.

Further studies considering the calorie intake and energy expenditure, physical activity, nutrition, and sleeping harmony, and recording the follow-up effects of RF may provide more detailed findings related to the effects of RF on health.

**Conflict of interest**

The authors declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

**References:**

1. Athyros VG, Tzilomalous K, Karagiannis A et al: Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets, 2010; 11(1): 122–35
2. Bozorgmamesh M, Hadaegh F, Khalili D, Azizi F: Prognostic Significance of the Complex “Visceral Adiposity Index” vs. Simple Anthropometric Measures. Cardiovasc Diabetol, 2012; 11(20): 1–10
3. Lee CMY, Huxley RR, Wildman RP, Woodward M: Indices of abdominal obesity are better discriminators of cardiovascular risk factor than BMI: a meta-analysis. J Clin Epidemiol, 2008; 61(7): 646–53
4. Bergman RN, Stefanovski D, Buchanan TA et al: A better index of body adiposity. Obesity (Silver Spring), 2011; 19(5): 1083–89
5. Amato MC, Giordano C, Galla M et al: Visceral adiposity index: a reliable indicator of visceral fat accumulation associated with cardiovascular risk. Diabetes Care, 2010; 33(4): 920–22
6. Du T, Sun X, Hoo R, Yu X: Visceral adiposity index, hyperglycemic cardiac dysfunction and risk of diabetes: the China Health and Nutrition Survey 2009. Int J Obes, 2013; [Epub ahead of print]
7. Boucher J, Masri B, Daviaud D et al: Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology, 2005; 146(4): 1764–71
8. Kleinz Ml, Davenport AP: Emerging roles of apelin in biology and medicine. Pharmacol Ther, 2005; 107(2): 198–211
9. Li L, Yang G, Li Q et al: Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes, 2006; 114(10): 544–48
10. Belfowski J: Apelin and visfatin: unique “beneficial” adipokines upregulated in obesity? Med Sci Monit, 2006; 12(6): RA112–19
11. Castan-Laurell I, Viltkova M, Daviaud D et al: Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol, 2008; 158(6): 905–10
12. Krist J, Wieder K, Klötting N et al: Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts, 2013; 6(1): 57–69
13. Heinonen MW, Laaksonen DE, Karhu T et al: Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis, 2009; 19(9): 626–33
14. Lv SY, Yang YJ, Chen Q: Regulation of feeding behavior, gastrointestinal function and fluid homeostasis by apelin. Peptides, 2013; 44: 87–92
15. Llorens-Cortés C, Beaudet A: Apelin, a neuropeptide that counteracts vasopressin secretion. Med Sci (Paris), 2005; 21(8–9): 741–46
16. Lv SY, Yang YJ, Qin YJ et al: Effect of centrally administered apelin-13 on gastric emptying and gastrointestinal transit in mice. Peptides, 2011; 32(5): 978–82
17. Wang G, Anini Y, Wei W et al: Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology, 2004; 145: 1342–48
18. Aydin S, Eren MN, Sahin I, Aydin S: The Role of Apelins in the Physiology of the Heart. Protein Pept Lett, 2014; 21(1): 2–9
19. http://www.who.int/mediacentre/factsheets/fs311/en/
20. Pischon T, Boeing H, Hoffmann K et al: General and abdominal adiposity and risk of death in Europe. N Engl J Med, 2008; 359(20): 2105–20
21. Flegal KM, Graubard BI, Williamson DF, Gail MH: Excess deaths associated with underweight, overweight, and obesity. JAMA, 2005; 293: 1861–67
22. Carmienke S, Freitag MH, Pischon T et al: General and abdominal obesity parameters and their combination in relation to mortality: a systematic review and meta-regression analysis. Eur J Clin Nutr, 2013; 67: 573–85
23. Yucel A, Degirmenci B, Acar M et al: The effect of fasting month of Ramadan on the abdominal fat distribution: assessment by computed tomography. Tohoku J Exp Med, 2004; 204(3): 179–87
24. Trepanowski JF, Bloomer RJ: The impact of religious fasting on human health. Nutr J, 2010; 9: 57
25. Sadeghirad B, Motaghpisheh S, Kolahdooz F et al: Islamic fasting and weight loss: a systematic review and meta-analysis. Public Health Nutr, 2012; 16: 11–17
26. Kul S, Savaş E, Oztürk ZA, Karadağ G: Does Ramadan Fasting Alter Body Weight and Blood Lipids and Fasting Blood Glucose in a Healthy Population? A Meta-analysis. J Relig Health, 2013 [Epub ahead of print]
27. Azizi F: Islamic fasting and health. Ann Nutr Metab, 2010; 56(4): 273–82
28. Unalacak M, Kara IH, Baltaci D et al: Effects of Ramadan fasting on biochemical and hematological parameters and cytokines in healthy and obese individuals. Metab Syndr Relat Disord, 2011; 9(2): 157–61
29. Ziaee V, Razaei M, Ahmadinejad Z et al: The changes of metabolic profile and weight during Ramadan fasting. Singapore Med J, 2006; 45: 409–14
30. Mansi KMS: Study the Effects of Ramadan Fasting on the Serum Glucose and Lipid Profile among Healthy Jordanian Students. American Journal of Applied Sciences, 2007; 4(8): 565–69